证券代码：002746 证券简称：仙坛股份 公告编号：2025-050 山东仙坛股份有限公司 第五届监事会第十次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 山东仙坛股份有限公司（以下简称"公司"）第五届监事会第十次会议通知 于 2025 年 8 月 12 日以书面方式送达全体监事，会议于 2025 年 8 月 23 日在公司 三楼会议室以现场方式召开，会议应到监事 3 人，实到监事 3 人，会议由监事会 主席冷胡秋先生主持。本次会议的召集、召开符合《公司法》和《公司章程》的 有关规定。 会议以记名投票表决方式审议并通过如下决议： 一、审议通过《公司 2025 年半年度报告》全文及其摘要 《公司 2025 年半年度报告》全文详见本公司指定信息披露网站巨潮资讯网 （www.cninfo.com.cn）。 《公司 2025 年半年度报告摘要》详见公司指定信息披露媒体《中国证券报》、 《证券时报》、《上海证券报》、《证券日报》及巨潮资讯网（www.cninfo.com.cn）。 表决结果：3 票同意，0 票反对，0 票弃权。 二、审议通过《公司 20 ...

山东仙坛股份有限公司 第五届董事会第十四次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 山东仙坛股份有限公司（以下简称"公司"）第五届董事会第十四次会议于 2025 年 8 月 23 日在公司三楼会议室以现场方式召开，通知已于 2025 年 8 月 12 日以通讯、书面方式送达公司全体董事。本次会议由董事长王寿纯先生主持，会 议应出席董事 7 人，实际出席会议董事 7 人，公司监事和高级管理人员列席会议。 本次会议的召集、召开符合《中华人民共和国公司法》和《公司章程》的规定。 会议以记名投票表决方式审议并通过如下决议： 证券代码：002746 证券简称：仙坛股份 公告编号：2025-049 二、审议通过《公司 2025 年半年度募集资金存放与使用情况的专项报告》 公司严格按照《公司法》《证券法》《深圳证券交易所股票上市规则》《深圳 证券交易所上市公司自律监管指引第1号——主板上市公司规范运作》《山东仙坛 股份有限公司募集资金管理制度》等规定使用募集资金，并及时、真实、准确、 一、审议通过《公司 2025 年半年度报告》全文及其摘要 公司的董事、 ...

证券代码：002746 证券简称：仙坛股份 公告编号：2025-047 山东仙坛股份有限公司 2025 年半年度利润分配预案的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、审议程序 山东仙坛股份有限公司（以下简称"公司"）于 2025 年 7 月 15 日披露了《关 于收到董事长 2025 年半年度现金分红提议的公告》（公告编号：2025-039），公 司控股股东、实际控制人、董事长王寿纯先生建议公司开展 2025 年半年度现金 分红安排，提议如下：以公司未来实施分配方案时股权登记日的总股本为基数， 向全体股东每 10 股派发现金红利人民币 1.00 元（含税），不送红股、不以资本 公积金转增股本。若在分配方案实施前公司总股本发生变化，将按照分配比例不 变的原则对分配总额进行调整。具体利润分配方案将由公司结合自身经营情况并 报董事会以及股东大会审议确定。 公司于 2025 年 8 月 22 日召开第五届董事会独立董事专门会议 2025 年第二 次会议，会议以 3 票同意、0 票反对、0 票弃权的表决结果审议通过了《公司 2025 年半年度利润分配预 ...

山东仙坛股份有限公司 2025 年半年度报告全文 山东仙坛股份有限公司 2025 年半年度报告 2025 年 08 月 1 山东仙坛股份有限公司 2025 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容 的真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担 个别和连带的法律责任。 1、禽类疫病及重大自然灾害发生引致的风险 鸡在饲养过程中会发生疫病，包括禽流感或其他类似疫症，因此，公司 经营过程中将会面临鸡发生疫病和养殖行业爆发大规模疫病传播导致的风险。 具体包括：（1）鸡因感染疾病死亡，鸡只出栏量下降直接影响公司生产经营 业绩；（2）疫病发生后，公司需对养殖场净化，净化过程增加生产成本； （3）疫病传播开始，公司需要增加防疫投入，包括实施强制疫苗接种、隔离 甚至扑杀等导致的支出或损失；（4）由于宰前、宰中未将商品代肉鸡潜在疫 病检出，病鸡进入加工环节，致使产品违反食品卫生规定，公司面临索赔和 处罚；（5）疾病感染与疫症传播（如禽流感）影响消费者心理和信心，导致 市场需求萎缩，产品价格下降，对鸡肉生产企业的生产经营造成不利影响。 如果 ...

Investment Rating - Industry rating: Outperform the market (maintained rating) [9] Core Insights - The pet industry is experiencing significant growth, with the Asia Pet Expo showcasing over 2,600 exhibitors and 20,000 brands, indicating a thriving market driven by globalization and innovation [2][13] - China's pet food exports have shown continuous growth, with 201,000 tons exported from January to July 2025, reflecting a year-on-year increase of 6.64% [14] - The pig farming sector is facing challenges, with the average pig price at 13.82 yuan/kg, a decrease of 3.63% from the previous week, and the average weight of pigs reaching a historical high [15][16] - The dairy sector is poised for a recovery, with the original milk price expected to rebound as production capacity decreases after a prolonged period of losses [17][18] - The poultry sector is focusing on breeding gaps, with a significant decline in the import of breeding chickens due to avian influenza concerns, which may impact future supply [19][20] - The planting sector emphasizes food security and the importance of biotechnology, with a focus on high-yield and resilient crop varieties [25] - The feed sector is recommended for investment, particularly in companies like Haida Group, which is expected to benefit from market recovery and increased market share [26] Summary by Sections Pet Sector - The Asia Pet Expo has reached a record scale of 310,000 square meters, highlighting the industry's vitality and innovation potential [2][13] - Pet food exports from China have increased, with a total of 201,000 tons exported in the first seven months of 2025, showing a year-on-year growth of 6.64% [14] - Recommended companies include pet food brands like Guibao Pet, Zhongchong Co., and Petty Co. [14] Pig Sector - The average pig price is currently at 13.82 yuan/kg, with a year-to-date low in profitability for pig farming [15][16] - The average weight of pigs is at a historical high, indicating supply pressures [15] - Recommended companies include leading pig farming firms such as Wens Foodstuffs Group and Muyuan Foods [16] Dairy Sector - Yuran Dairy reported stable performance with a revenue of 10.3 billion yuan, showing a year-on-year growth of 2.3% [17] - The dairy industry is expected to see a recovery as production capacity decreases [18] - Recommended companies include Yuran Dairy and China Shengmu Organic Milk [18] Poultry Sector - The poultry sector is facing challenges with breeding imports, particularly for white chickens, due to avian influenza [19][20] - Recommended companies include Shennong Development and Yisheng Livestock [20] Planting Sector - The focus is on food security and biotechnology, with an emphasis on high-yield and resilient crop varieties [25] - Recommended companies include Longping High-Tech and Dabeinong Technology Group [25] Feed Sector - Haida Group is highlighted as a key investment opportunity due to its increasing market share and performance [26] - The animal health sector is also recommended, particularly companies like Kexin Biological [27]

又一单券业并购拿下批文！ 8月22日证监会核准国信证券成为万和证券主要股东，核准深圳市投资控股有限公司成为万和证券实际控制人。这意味着该并购重组项目正式注册生效。 | 序号 上市公司 板块 | | | | | | --- | --- | --- | --- | --- | | (002746国信证 主板 发行股份购 注册生效 资本市场服务 第一创业承销 北京市天元律 天健会计师事务 2025-08-22 2025-04-10 | | | | | | 券 | 英资产 | 保存 | 师事务所 | 所(特殊普通合 | | 伙) | | | | | 下一步，国信证券将会同万和证券按照报送证监会的初步整合方案确定的方向，在一年内制定并上报具体整合方案，明确时间表。 又一券业并购获得批文 具体来看，2024年9月国信证券披露收购预案，12月初披露草案，同月下旬交易事项获得深圳市国资委批复以及通过股东大会审议。直至今年4月该交易事项才步 入交易所审核流程。监管审核进展方面，项目经历一轮问询后在6月19日顺利上会。最终，项目从受理到获得批文耗时4个月。 相比最初并购方案，7月28日国信证券发布的《关于发行股份购买资产暨关联交 ...

证券之星消息，8月20日养殖业板块较上一交易日上涨0.91%，天域生物领涨。当日上证指数报收于 3766.21，上涨1.04%。深证成指报收于11926.74，上涨0.89%。养殖业板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 603717 | 天域生物 | 8.36 | 2.58% | 16.26万 | | 1.35亿 | | 002299 | 圣农发展 | 17.21 | 1.77% | 23.18万 | | 3.96亿 | | 002714 | 牧原股份 | 47.50 | 1.69% | 40.97万 | | 19.30亿 | | 600965 | 福成股份 | 5.25 | 1.55% | 13.32万 | | 6923.09万 | | 002746 | 仙坛股份 | 6.39 | 0.95% | 10.32万 | | 6555.82万 | | 000048 | 京基督农 | 16.00 | 0.88% | 5.88万 | | 9350.98万 ...

Core Viewpoint - Several companies, including Xiantan Co., are planning significant investments in securities, raising concerns about potential risks associated with diverting funds from core business operations [1][2]. Group 1: Company Investment Plans - At least seven companies have announced plans to invest over 1 billion RMB in securities, with Xiantan Co. planning to use up to 1 billion RMB of its own funds for this purpose [1]. - Xiantan Co. reported a net asset of 4.664 billion RMB at the end of 2024, with the planned investment amounting to approximately 21% of its net assets [1]. - The company’s revenue for 2024 was 5.291 billion RMB, reflecting a year-on-year decline of 8.49%, while net profit decreased by 8.75% to 206 million RMB [1]. Group 2: Financial Performance and Risks - Xiantan Co. experienced a significant drop in operating cash flow, down 52.9% to 155 million RMB, while capital expenditures increased to 586 million RMB, indicating tightening cash flow [1]. - The decision to allocate 1 billion RMB for securities investment amidst declining cash flow raises concerns about the potential strain on the company's core business operations [2]. - Industry experts suggest that the focus on securities investment could lead to insufficient investment in core operations, potentially resulting in increased costs and underperformance in production capacity [2][3]. Group 3: Regulatory and Investor Considerations - There is a call for regulatory measures to limit the proportion of securities investments by listed companies and to ensure transparency in investment logic and risk management [3]. - Companies are encouraged to maintain their core business focus and treat securities investment as a supplementary strategy rather than a primary activity [3]. - Investors are advised to prioritize the long-term competitiveness and sustainability of the company's main business over short-term fluctuations in investment returns [3].

Group 1 - The A-share market for chicken industry stocks experienced a significant rally, with companies like Xiaoming Co. rising nearly 14%, Minhe Co. up over 8%, and Yisheng Co. increasing by nearly 6% [1] - The price of white feather chicken has seen extreme fluctuations, dropping below 3 yuan per jin in early July, leading to deep losses in the industry. To mitigate excess supply, some breeding farms have resorted to extreme measures such as culling breeding chickens [1] - By August, the price of毛鸡 surged to a peak of 3.7 yuan per jin, while chick prices skyrocketed from 1.5 yuan per chick to 4.2 yuan per chick, marking an increase of 180%. The demand for chicks remains high despite the price surge [1] - Since July, domestic chick prices have entered a rising trend, with a staggering increase of 300% in Shandong, a major meat chicken production province, over just a month [1]

Core Viewpoint - The surge in the Shanghai Composite Index from around 3000 points in April to over 3600 points has led to a noticeable increase in the enthusiasm of listed companies for stock trading, with 57 companies announcing plans to use idle funds for securities investment [1] Group 1: Company Investment Trends - 57 listed companies have announced plans to use their idle funds for securities investment this year [1] - Companies such as Liou Co., Fangda Carbon, Seven Wolves, Tapa Group, Lianfa Co., Xiantan Co., and Zhejiang Yongqiang plan to invest over 1 billion yuan in securities [1] - Liou Co. leads with a proposed investment of 3 billion yuan, while Fangda Carbon and Seven Wolves plan to invest over 2 billion yuan each [1] Group 2: Company Profitability - Most companies engaging in stock trading are from traditional manufacturing sectors such as electric equipment, construction decoration, and steel [1] - Out of the 57 companies, 52 are expected to be profitable in 2024 [1] - The five companies projected to incur losses in 2024 include Buchang Pharma, Haixiang Pharma, Liou Co., Zhongke Jincai, and Baibang Technology [1] Group 3: Notable Losses - Buchang Pharma and Haixiang Pharma are expected to incur significant losses of 550 million yuan and 330 million yuan respectively in 2024, yet they still plan to allocate 30 million yuan and 70 million yuan for securities investment [1]